The Current Landscape of Immune Checkpoint Inhibition for Solid Malignancies

Surg Oncol Clin N Am. 2019 Jul;28(3):369-386. doi: 10.1016/j.soc.2019.02.008.

Abstract

Immunotherapy has led to unprecedented improvement in the treatment and prognosis of high-risk resectable and metastatic disease across cancer types. Nowhere is this better highlighted than in the management of advanced and metastatic melanoma with the introduction of molecularly targeted therapies and immune checkpoint inhibitors. Following their success in melanoma, immunotherapies have also been evaluated and their use approved in the management across a variety of other solid malignancies in the neoadjuvant, adjuvant, and advanced/metastatic setting. This review provides an overview of the current landscape of immune checkpoint inhibition for solid malignancies.

Keywords: CTLA-4; Immune checkpoint; Melanoma; Non–small cell lung carcinoma; PD-1; PD-L1; Renal cell carcinoma; Urothelial carcinoma.

Publication types

  • Research Support, N.I.H., Extramural
  • Review

MeSH terms

  • Animals
  • Antibodies, Monoclonal / therapeutic use*
  • Antigens, Neoplasm / immunology*
  • Cell Cycle Checkpoints / drug effects*
  • Humans
  • Immunotherapy / methods*
  • Molecular Targeted Therapy*
  • Neoplasms / immunology
  • Neoplasms / therapy*

Substances

  • Antibodies, Monoclonal
  • Antigens, Neoplasm